Issue 14 · Nov 2–8, 2026Agent Age News magazine · Other editions · Method · HU / ENG

How AI is affecting healthcare, medicine and drug development, curated weekly

regulation · United States

FDA discussion paper would assess generative AI devices in a way similar to doctors

Aug 17, 2026 · Issue 3 · 20 sources, 20 articles

On August 18, the FDA published a discussion paper on regulating generative AI-enabled medical devices: benchmarks would come first, then clinical confirmation, and finally evaluation of real-world use. Manufacturers, physicians and researchers can submit comments on document FDA-2026-N-7874 until October 19.

Who is affected and how

medtech company
During the comment period, companies should indicate which tier of the proposed graduated assessment their product would fall into and what evidence they can provide for it.
doctor
Through professional organizations, physicians can have a say in what clinical confirmation generative AI tools should be required to show.
health IT
Teams need to assess which embedded generative functions could fall under device regulation.
health policy
The FDA is signaling a direction for authorizing generative AI, which may serve as a benchmark for other regulators.

Narrative: AI must be licensed as a doctor

Sources

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.